
Evommune, Inc. (NYSE:EVMN – Free Report) – Stock analysts at HC Wainwright lifted their FY2026 earnings per share estimates for shares of Evommune in a research note issued on Friday, November 13th. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings of ($3.28) per share for the year, up from their previous estimate of ($3.41). HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Evommune’s current full-year earnings is ($3.37) per share. HC Wainwright also issued estimates for Evommune’s Q4 2026 earnings at ($0.88) EPS, Q1 2027 earnings at ($0.84) EPS, Q2 2027 earnings at ($0.83) EPS, Q3 2027 earnings at ($0.86) EPS, Q4 2027 earnings at ($0.91) EPS and FY2027 earnings at ($3.45) EPS.
Evommune (NYSE:EVMN – Get Free Report) last issued its quarterly earnings results on Thursday, November 12th. The company reported ($0.85) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.03).
Read Our Latest Analysis on Evommune
Evommune Stock Down 1.8%
Evommune stock opened at $6.89 on Tuesday. The stock’s 50 day moving average is $7.25 and its 200 day moving average is $16.91. Evommune has a one year low of $4.94 and a one year high of $33.20.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Janus Henderson Group PLC bought a new stake in shares of Evommune during the 1st quarter valued at about $20,615,000. Defilade Capital Management L.P. grew its stake in Evommune by 215.0% during the first quarter. Defilade Capital Management L.P. now owns 678,589 shares of the company’s stock worth $15,601,000 after purchasing an additional 463,171 shares during the period. Perceptive Advisors LLC acquired a new stake in Evommune during the first quarter worth approximately $10,308,000. Baker BROS. Advisors LP increased its holdings in Evommune by 45.7% in the third quarter. Baker BROS. Advisors LP now owns 1,234,794 shares of the company’s stock worth $10,199,000 after purchasing an additional 387,404 shares in the last quarter. Finally, Velan Capital Investment Management LP increased its holdings in Evommune by 1.1% in the second quarter. Velan Capital Investment Management LP now owns 451,255 shares of the company’s stock worth $5,997,000 after purchasing an additional 5,000 shares in the last quarter.
Evommune Company Profile
Evommune is a clinical-stage biotechnology company developing therapies for chronic inflammatory diseases. Founded in 2020, the company focuses on biological pathways involved in inflammation and aims to develop treatments for conditions with significant unmet medical needs. Its pipeline includes EVO756, an oral investigational medicine designed to block MRGPRX2, a receptor involved in mast-cell activation. The candidate is being studied for inflammatory skin disorders, including chronic spontaneous urticaria and atopic dermatitis.
Featured Articles
- Five stocks we like better than Evommune
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Evommune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evommune and related companies with MarketBeat.com's FREE daily email newsletter.
